"Rising Colorectal Cancer Incidence and Demand for Early, Non-Invasive Diagnostics Propel Global Market Growth Across Test Types, End Users and Regions"
BOSTON, June 4, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Global Colorectal Cancer Screening and Diagnostics Market" is projected to grow from $40.0 billion in 2024 to $46.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 2.9% from 2024 through 2029.
The report provides a detailed overview including market trends, dynamics, and emerging technologies. It highlights drivers, challenges, and opportunities within the industry and features comprehensive profiles of leading manufacturers and service providers such as Fujifilm Holdings Corporation, Olympus Corporation, Exact Sciences Corporation, Danaher Corporation, Guardant Health, New Horizon Health, and Quest Diagnostics.
The report offers market projections and application forecasts for the next five years and analyze major companies' financials, product portfolios and recent activities.
The factors driving the market's growth include:
Increasing Incidence of Colorectal Cancer: More people are being diagnosed with colorectal cancer, especially younger adults, due to lifestyle and genetic factors.
Growing Financial Burden: The high costs of treatment and care for colorectal cancer drive the need for cost-effective screening and diagnostics.
Advances in Genomics and Molecular Diagnostics: New technologies in genomics are improving the accuracy and personalization of colorectal cancer diagnostics.
Rise in Demand for Non-Invasive Screening: Non-invasive tests like stool and blood tests are becoming more popular, making screening easier and more accessible.
Need for Early Detection: Early detection of colorectal cancer reduces treatment costs and improves survival rates, pushing the adoption of advanced screening technologies.
Request a sample copy of the global colorectal cancer screening and diagnostic testing service market report.
Report Synopsis
Report Metric | Details |
Base year considered | 2023 |
Forecast period considered | 2024-2029 |
Base year market size | $39.0 billion |
Market size forecast | $46.1 billion |
Growth rate | CAGR of 2.9% for the forecast period of 2024-2029 |
Segments covered | Test type, end-use industry and region |
Regions covered | North America, Europe, Asia-Pacific and Rest of the World (RoW) |
Countries covered | The U.S., Canada, Mexico, Germany, France, Italy, Spain, the U.K., the Netherlands, Poland, the Czech Republic, Hungary, Austria, Slovakia, Slovenia, China, India, Japan, South Korea, Australia, Thailand, Singapore, Vietnam, South America, Middle East and Africa |
Market drivers | • Increasing incidence of colorectal cancer. • High treatment cost. • Advances in genomics and molecular diagnostics. • Rise in demand for non-invasive colorectal cancer screening. • Growing need for early cancer detection to lower treatment costs. |
Interesting facts:
- At-home stool-based tests, such as FIT and Cologuard, are gaining popularity for their convenience and effectiveness, boosting screening compliance rates.
- Treating late-stage colorectal cancer can cost up to three times more than early-stage treatment, emphasizing the economic benefits of widespread screening programs.
- In early trials, artificial intelligence has shown the ability to detect cancers, such as colorectal cancer, with accuracy rates comparable to or even better than those of human radiologists.
Emerging startups:
- Freenome Holdings, Inc.
- GI-View
- Geneoscopy, Inc.
- AcuamarkDx.
The report addresses the following questions:
- What is the market's projected size and growth rate?
- The colorectal cancer screening and diagnostic testing service market is projected to grow from $39.0 billion in 2023 to $46.1 billion in 2029 at a CAGR of 2.9% during the forecast period. - What are the key factors driving the growth of the market?
- The increasing incidence of colorectal cancer.
- The upsurge in the financial burden on healthcare associated with colorectal cancer.
- Advancements in genomics and molecular diagnostics.
- The rise in demand for non-invasive colorectal cancer screening.
- The growing need for early cancer detection to lower treatment costs. - What market segments are covered in the report?
- The market is segmented based on test type, end user, and region. - Which segment will dominate the market by the end of 2029?
- The colonoscopy and sigmoidoscopy test type segment will dominate the market by the end of 2029. - Which region has the largest market share?
- North America holds the largest share of the global market.
Leading companies include:
- EXACT SCIENCES CORP.
- DANAHER CORP.
- DIACARTA
- EIKEN CHEMICAL CO. LTD.
- FREENOME HOLDINGS INC.
- FUJIFILM HOLDINGS CORP.
- GI-VIEW
- GUARDANT HEALTH
- HANGZHOU NOVAHEALTH TECHNOLOGY CO. LTD.
- LABORATORY CORPORATION OF AMERICA HOLDINGS
- LEPU MEDICAL TECHNOLOGY (BEIJING) CO. LTD.
- MAINZ BIOMED N.V.
- NOVIGENIX SA
- OLYMPUS CORP.
- QUEST DIAGNOSTICS INC.
- QUIDELORTHO CORP.
Related Reports Include:
Routine Health Screening Market: The routine health screening market is rapidly expanding due to the increasing focus on preventive healthcare and the rising incidence of non-communicable diseases like diabetes and cardiovascular disorders. Technological advancements, such as AI integration in diagnostic tools, have improved the accuracy and accessibility of screenings. The COVID-19 pandemic has highlighted the importance of regular health check-ups, further boosting the market. Additionally, the incorporation of screenings into corporate wellness programs and the trend toward personalized medicine drive growth. This market will be crucial in global proactive and personalized health management.
Navigate Uncertainty with Confidence
In times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights.
Purchase a copy of the report directly from BCC Research.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement, and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA
Email: info@bccresearch.com
Phone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo - https://mma.prnewswire.com/media/2183242/5353934/BCC_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-colorectal-cancer-screening-and-diagnostics-market-to-reach-46-1-billion-by-2029--302473641.html
